Background {#Sec1}
==========

The treatment gap is an important concept in global health advocacy with applicability across a range of chronic medical conditions such as HIV/AIDS \[[@CR1]\], hypertension \[[@CR2]\], cardiovascular diseases \[[@CR3]\], diabetes \[[@CR3]\], epilepsy \[[@CR4]\] and mental disorders \[[@CR5]\]. For all conditions, the treatment gap is defined as the proportion of people with disorder who require an intervention but do not receive one. The treatment gap for mental disorders is universally large, although particularly marked in low and middle-income countries (LMIC) \[[@CR5], [@CR6]\], with almost four out of five persons with severe mental disorders in LMIC receiving no treatment in the previous year \[[@CR7], [@CR8]\]. This is even larger in sub-Saharan Africa with nine in ten people with schizophrenia not receiving care \[[@CR9], [@CR10]\]. In Ethiopia, the Butajira study on the course and outcome of severe mental illnesses 15 years ago, reported a lifetime treatment access gap for schizophrenia and bipolar disorder of 90% \[[@CR11], [@CR12]\], with similar national rates more recently \[[@CR9]\].

The treatment gap is an indicator of the extent to which a health system fails to meet the care needs of people with a specific disorder at the population level. As such, changes in the treatment gap is an important metric for tracking progress in improving treatment coverage in moving towards universal health care \[[@CR13]\]. However, current measures of the treatment gap, consisting of direct and indirect approaches, are conceptually inadequate and are criticised for ignoring the broader range of services or 'plurality' of care \[[@CR14]\]. The potential negative consequences of not receiving care, particularly relevant in places with high 'treatment gap', where potential for human rights violations may be substantial \[[@CR15]\], are also overlooked. Thus, broadening the definition and applicability of the treatment gap to varied contexts, interventions and outcomes is pertinent. In this paper we re-conceptualise the treatment gap as a multi-dimensional construct and evaluate its burden in people with psychosis at the point of engagement with a new integrated service in rural Ethiopia.

Re-conceptualising the treatment gap {#Sec2}
------------------------------------

Our re-conceptualisation is based on two premises. First, as indicated above, is the need to consider the plurality of care and the power of individuals to use the care they choose. The service pyramid of the WHO \[[@CR16]\] is a useful framework for defining and measuring this plurality of care. In addition to biomedical care, it is contextually appropriate to quantify access to FTH providers as well as support from the community, non-governmental organisations, family and self-care. The second premise is the need to move away from treatment for a disorder to the goal of treatment, "recovery" and "recovery" gap with emphasis on what is meaningful to the person in need. In this regard, the treatment gap is viewed as a continuum, with the continuum moving from lack of access to any evidence-based care during the whole duration of the illness (lifetime access gap) to failure to achieve the goal of treatment, recovery (recovery gap) (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). The most severe form of access gap is the *lifetime access gap*, which provides information about the severity of population level neglect, and may have particular relevance in LMIC settings. Table 1Definitions of the treatment gap dimensions and how they may be measuredCare/treatment gap dimensionsDefinitionHow measuredSubjectiveObjectiveAccess• LifetimeWhether there 'ever' was access to evidence-based care since onset of illness without any judgment about efficacySelf-reported access over the course of illness since onsetLinkage based on databases (electronic or other records)• CurrentWhether there was access to evidence-based care for the current or most recent episode of illnessSelf-reported access during the current or most recent episode of illnessLinkage based on databases (electronic or other records)AdequacyWhether adequate quantity of treatment was provided in terms of the nature, dose and duration of treatmentSelf-reported minimum adequacy standardRecorded information compared with established standard of careQualityAttainment of a certain standard and meeting certain intrinsic characteristics of care such as patient satisfaction and concordance with patient valuesSelf-reported patient satisfactionEvaluation of whether care is concordant with established quality standards and guidelinesEffectivenessIntended outcomes of clinical improvement achieved with little untoward consequences and inconvenience to userSelf-reported benefit of careStandard scales of effectivenessRecoveryThis is the ultimate goal of treatment and understood in three ways:• Sustained clinical wellness (well for at least 6 months)• Functional wellness (regaining full functionality)• As a process of change that allows individuals to "improve their health and wellness, live a self-directed life, and strive to reach their full potential" \[[@CR17]\]Self-reported recoveryStandard scales of recovery may be usedEquityIs relevant to all dimensions of care or treatment gap and equitable care ensures that access, quality or impact of care "does not vary in quality because of personal characteristics such as gender, race, ethnicity, geographical location, or socioeconomic status."Analysis of variation of care and treatment gap by the various equity dimensions. Fig. 1Dimensions of the treatment gap continuum. It is hypothesized that lifetime access gap would be the smallest, while recovery gap would be the largest. Equity (whether access to adequate, quality and effective treatment provision is affected by various personal and demographic characteristics) is relevant to all the treatment gap types

The *quality and adequacy gaps* are directly relevant to effectiveness and recovery gaps. Although 'quality' has several meanings in health service research, the quality gap here represents how different the care provided is to accepted quality standards or treatment guidelines and to implicit requirements such as patient satisfaction \[[@CR18]\].

The *adequacy gap* relates to the adequacy of treatment in terms of dose/intensity, continuity and duration. A simple method of measuring the adequacy gap may be assessing the frequency of service encounters in combination with the appropriateness of the prescribed treatment \[[@CR19]\]. Ultimately, the goal of treatment is to achieve full recovery \[[@CR20]\]; thus, the target goal for policy initiatives and care provision has to be to reduce the recovery gap. The recovery gap is an important indicator of the inadequacies of the implementation of current evidence-based care. For example, a large proportion of patients receiving treatment for severe \[[@CR21]\] or less severe illnesses \[[@CR22]\] fail to achieve recovery.

There are two additional dimensions, which are of major importance: equity and impact or consequence. *Equity* is a cross-cutting dimension and a reflection of whether the lack of treatment or the benefits of treatment are distributed across the whole population in need without discrimination. The final dimension of the treatment gap evaluates the *consequence* or impact of the treatment gap on the affected individual, family and the wider community. Estimating the consequences of the treatment gap will show why the treatment gap matters. In addition to the direct illness burden, one of the key consequences of the treatment gap is human rights abuse from various sources including through the process of receiving care.

Redefining the treatment gap in this more nuanced multi-dimensional way extends applicability to ore settings and allows for a more refined analysis and identification of targeted policy interventions.

The aim of this study was to determine the various dimensions of the treatment gap for psychosis in a setting where a new service programme, the Programme for Improving Mental Healthcare (PRIME) \[[@CR23]\], was being implemented.

Methods {#Sec3}
=======

The study was a cross-sectional assessment of adults with confirmed diagnosis of psychosis. The study participants were identified through community case detection and subsequent structured clinical evaluation of diagnosis.

Setting {#Sec4}
-------

The study was conducted in the Sodo district, Gurage Zone, Southern Nations, Nationalities and Peoples' Region (SNNPR) of Ethiopia. We have reported previously on the study setting \[[@CR24], [@CR25]\]. Sodo is a predominantly rural district located about 100 km south of the capital city, Addis Ababa. The district hosts one primary hospital, eight health centres and 58 health posts (community based health facilities).

Case identification {#Sec5}
-------------------

We used a two-stage case identification process for recruiting participants (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Flow diagram of patient recruitment (\*Assuming 54% of the total population to be adults)

First, potential cases with psychosis were identified and referred by community key informants \[[@CR26]\], consisting of health extension workers and community leaders trained for half a day by a psychiatrist with experience in training key informants. Health extension workers are healthcare staff with one year of training in healthcare after completing high school education. They staff the health posts located within the communities and also reside within the communities they serve. These health workers visit households about once a month and have intimate knowledge of their communities. Second, these potential cases were referred to the health centres where trained psychiatric nurses conducted a semi-structured interview to confirm diagnosis and evaluate other clinical parameters, such as symptom severity. To be included in the study, participants had to be at least 18 years of age, fulfil diagnostic criteria of the International Classification of Diseases (ICD) \[[@CR27]\] for one of the major psychotic disorders ((ICD-10 F20 and ICD-10 F30 \[psychotic subsections\]), be in need of mental health care at the time of detection, and were resident in the area for at least six months. The study was conducted between December 2014 and August 2015.

Assessment of diagnosis and other clinical and social parameters {#Sec6}
----------------------------------------------------------------

The Operational Criteria for Research (OPCRIT) \[[@CR28]\], a semi-structured checklist for genetic studies, was used to support clinical diagnosis. The instrument uses some of the rating styles of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) \[[@CR29]\] but is briefer and simpler to administer. It has established reliability and allows application of multiple diagnostic criteria \[[@CR28]\].

Measurement of the treatment gap {#Sec7}
--------------------------------

The Butajira Treatment Gap Questionnaire (TGQ) was used to establish the treatment gap (available at <http://bit.ly/2oPlqmQ>). The TGQ is an 83 items questionnaire exploring receipt of: (1) biomedical care; (2) Faith and Traditional Healing (FTH); (3) Community care (assistance from community residents and leaders, religious institutions, social organisations, NGOs); (4) support from family and friends; (5) general self-care; (6) overall experience and impact or consequence of treatment gap and dignity in care. Details within these main dimensions explored four treatment gap themes or dimensions (Fig. [1](#Fig1){ref-type="fig"}): Access to care (lifetime and current access); adequacy of care (for the current access); quality of care (for the current access); and effectiveness of care (perceived benefit of care for the current access).

Adequacy of care was adapted from a study by Wang and colleagues that used frequency of visits as an indicator of adequacy \[[@CR19]\]. Thus, based on evidence from primary and speciality care, Wang and colleagues considered four or more visits of follow-up and medication monitoring for "acute and continuation phases of treatment for mood, anxiety and psychotic disorders" as minimally adequate. Quality of care was assessed through satisfaction with provided care. Effectiveness was measured from the participants' perspective, in terms of whether they felt they had benefited from or harmed by the treatment they received. Under the FTH section, 12 types of locally relevant "healing" providers were included. The most widely used FTH across the country is "Holy Water" treatment, in which water which has been sanctified through prayer is sprinkled on a patient for healing and protection. Finally, in a section on "dignity in care", the overall experience of care was assessed with a focus on negative experiences, including homelessness, accidents and assaults, restraint and imprisonment. The questions to estimate the treatment gap assessed positive care receipt from which the treatment gap was estimated.

The TGQ was developed as a pragmatic field tool by the Ethiopia team through a series of consensus meetings to agree on the key dimensions of the TG and how to measure these dimensions. The study was part of an initial pilot of the tool. We have not carried out formal validation study. Nevertheless, the reliability of the scale measured through the internal consistency coefficients, Cronbach's alpha, was generally satisfactory---highest score was obtained for perceived benefit in care or recovery (α = 0.97). The coefficient for quality of care was also good (α = 0.83).

Illness severity, and other measures {#Sec8}
------------------------------------

Clinical severity of symptoms was assessed with the Brief Psychiatric Rating Scale- Expanded version (BPRS- E) \[[@CR30]\], a 24-item instrument, which has been used previously in Ethiopia \[[@CR31]\]. The World Health Organization Disability Assessment Schedule (WHODAS 2.0, \[[@CR32]\]), which measures the level of difficulty in daily activities and social participation experienced in the previous 30 days \[[@CR33]\] and has been adapted for use in Ethiopia \[[@CR34], [@CR35]\] was employed to measure functional impairment. The quality of social support was assessed with the Oslo 3 Social Support Scale (OSS) \[[@CR36]\].

Administration of assessment instruments {#Sec9}
----------------------------------------

The main clinical assessment instruments (OPCRIT and BPRS-E) were administered by trained psychiatric nurses, while the TGQ and the other psychosocial scales were administered by trained lay data collectors. These data collectors were high school graduates with two to four years of additional technical or professional training. They were trained for five days for the data collection and by the time they administered these instruments they already had a one year experience of administering various instruments for the PRIME study.

Data management {#Sec10}
---------------

Data were double-entered into Epidata version 3.1 and analysed using STATA version 13.1 (StataCorp, 1985--2013). Simple descriptive analyses were used to summarise socio-demographic factors along with service use and treatment gap profiles.

An exploratory multivariable analysis was carried out using logistic regression to assess for factors associated with the use of biomedical services in the current access. The selected factors were considered theoretically relevant determinants of use of services, such as education, income, social support and service use behaviour as indicated by the use of FTH. Further exploratory analysis included evaluation of the potential link between adequacy of biomedical care and adverse experiences.

Results {#Sec11}
=======

Demographic and clinical characteristics {#Sec12}
----------------------------------------

A total of 300 participants were included in the study. Participants were predominantly of the Gurage ethnic origin (*n* = 285; 94.7%), Orthodox Christian (*n* = 271; 90.0%) and rural residents (*n* = 240; 80%). Men were slightly overrepresented (*n* = 173; 57.5%) (Table [2](#Tab2){ref-type="table"}). Over four fifths had a diagnosis of a schizophrenia spectrum disorder (*n* = 244; 81.3%) (Table [2](#Tab2){ref-type="table"}). A small minority had affective psychosis (*n* = 40; 13.3%). Overall, participants had a moderate severity of illness and disability measured with the BPRS-E (mean, SD = 47.3, 17.1) and WHODAS (mean, SD = 51.5, 23.5). Table 2Background characteristics of participants (*n* = 300 unless specified)CharacteristicsNumberPercentGenderMale17257.3Female12842.7Age18--246521.725--348227.335--447926.345--544615.355 and above289.3ResidenceUrban6020.1Rural23979.9EducationIlliterate11839.3No formal education but can read and write3913.0Formal education14347.7Employment (*n* = 299)Agricultural work7625.4self employed165.4House wife5819.4Other employment3913.0Unemployed11036.8Incomelow and below191.63.7Medium and above10936.3Marital statusSingle13645.3Married11137.0Divorced4013.3Widowed134.3ReligionOrthodox Christian27190.0Other3010.0Ethnicity (n = 299)Gurage28194.0Other186.0Children (*n* = 295)Yes15753.2No13846.8Children under 18 (*n* = 157)Yes12680.3Summary diagnosisSchizophrenia spectrum disorders25685.3Affective psychosis4414.7

The treatment gap {#Sec13}
-----------------

### Lifetime access gap {#Sec14}

The lifetime access to FTH was the highest (Table [3](#Tab3){ref-type="table"}), with 84.9% (*n* = 254) of participants having accessed this modality of care. Over half of the participants (58.2% (*n* = 174) had accessed biomedical care (specialist mental health services) at some point during the illness. Thus, the lifetime access gap was 15 and 41.8% for FTH and biomedical care respectively. Lifetime experience of admission (staying for at least 24 h in a facility for the purposes of treatment) for FTH was 76.3% (*n* = 229) and for biomedical care 21.3% (*n* = 64). Table 3Prevalence of care receipt by type of providerCare TypeNumberPercentInpatient care-Lifetime (n = 300)Biomedical6421.3FTH22976.3Inpatient care-Most recent episode (n = 300)Biomedical227.3FTH11438.0Outpatient care-Lifetime (n = 299)Biomedical17458.2FTH25484.9Outpatient care- Most recent episode (n = 299)Biomedical12040.1FTH16445.2Informal sector (lifetime)Family28695.7Neighbours6923.0Religious organisations3110.3Social groups (Idir)103.3NGOs51.7Friends (*n* = 292)4615.8Self-support/self help25785.7Community support6923.0*FTH* Faith and Traditional Treatment, *NGOs* Non-Governmental Organizations

### Current access gap {#Sec15}

Access to outpatient care for a biomedical psychiatric service provider was 40.1% (*n* = 120) and for that of FTH provider was 54.8% (*n* = 164) corresponding with a current access gap of 59.9% for biomedical care and 45.2% for FTH. A much lower proportion of people reported admission for their current episode either to psychiatric hospitals (n = 22; 7.3%) and/or FTH providers (*n* = 118; 38.0%).

### Adequacy, quality and equity gaps {#Sec16}

Regarding adequacy of biomedical care received in the current episode (Table [4](#Tab4){ref-type="table"}), 31.2% of those who accessed care (*n* = 34/109) reported minimally adequate care. This equates to only 11.3% of the total sample of participants (n = 34/300). The overall satisfaction in care, measuring the presumed construct of quality of care, was generally good, with 68.5% of those using biomedical care reporting satisfaction with the service. Table 4Adequacy, quality and perceived benefit of care for treatment in recent episodeService characteristicService typeBiomedicalFTHNPercentNPercentAdequacy of care(Biomedical = 109)^a^Inadequate treatment7568.8----^b^Minimally Adequate3431.2----Perceived benefit(N=Biomedical = 112)(N=Holy water = 149)Complete improvement3733.04932.9Some improvement6356.37651.0No improvement1210.72315.4Harm00.010.7Satisfaction in care (measuring quality)Biomedical (111)(FTH = 150)Very satisfied3425.52114.0Satisfied4643.05234.7Neutral2118.83221.3Dissatisfied78.13221.3Very dissatisfied34.7138.7^a^Data not collected for Faith & Traditional providers as there is no guideline for this*FTH* Faith and Traditional Treatment^b^Minimally adequate treatment defined as receipt of appropriate treatment with at least four monitoring visits

The perceived benefit and satisfaction measuring quality of care from biomedical care and a specific type of FTH (holy water) was comparable. However, other FTHs, in addition to having been used less, were considered of lower quality and associated with reports of higher harm.

Those with formal education (Adj. OR; 95% CI = 2.1; 1.2, 3.8) and those who had used FTH (Adj. OR; 95% CI = 3.2; 1.9, 5.4) were more likely to use biomedical care (Table [5](#Tab5){ref-type="table"}). Table 5Associations of selected patient characteristics and likelihood of receiving biomedical treatment in the last 12 monthsCharacteristicsResponse categoriesNumber interviewed% who received biomedical treatmentCrude Odds Ratio (95% Confidence Interval)Adjusted Odds Ratio (95%Confidence Interval)SexMale17236.6RefFemale12844.51.39 (0.87,2.21)1.55 (0.92, 2.61)ResidenceUrban6041.7RefRural23939.80.92 (0.52,1.64)1.11 (0.57,2.18)EducationIlliterate15732.5RefRead and write5337.71.26 (0.66,2.41)1.27 (0.62, 2.62)Formal Education8953.92.43 (1.43,4.15)2.40 (1.27,4.53)Relative wealthLow or very low19138.7RefMedium or above10942.21.15 (0.72,1.86)0.96 (0.57,1.62)Received traditional treatment in the last 12 monthsNo13625.0RefYes16452.43.31 (2.02,5.42)3.22 (1.90,5.49)Mean (SD)Age30035.5 (13.5)0.99 (0.97,1.00)1.00 (0.98,1.02)BPRSE29448.5 (15.6)1.00 (0.98,1.01)1.00 (0.98,1.02)Social support3009.4 (2.4)1.09 (0.99,1.21)1.06 (0.95, 1.19)*BPRSE* Brief Psychiatric Rating Scale Expanded Version

Potential consequences of the treatment gap {#Sec17}
-------------------------------------------

Several adverse outcomes and experiences were recorded (Fig. [3](#Fig3){ref-type="fig"}) although not all may be accounted for by the treatment gap. The most common were experiences of physical restraint, reported by 46.3% (*n* = 139) of participants. Experience of homelessness also affected more than a third of the sample (36.3%, *n* = 109). Other traumatic experiences included physical assault, sexual assault and accidents. Further exploration of the potential relationship between such adverse outcomes and adequacy of biomedical care suggested a link with not receiving minimally adequate biomedical treatment (See Additional file [1](#MOESM1){ref-type="media"}). However, in regression analysis, there was no significant association between the treatment gap and selected adverse outcomes (homelessness, restraint and assault) (Figures not shown). Fig. 3Potential consequences of the treatment gap

Access to other sources of care {#Sec18}
-------------------------------

The family was reported to be the main source of support for patients, with less than a quarter reporting any input from neighbours (23.0%), friends (15.8%), the community (23.0%), social organisations (3.3%), religious institutions (10.3%) or NGOs (1.7%). On the other hand, almost the same proportion who reported support also reported harm from these resources.

Discussion {#Sec19}
==========

To our knowledge this is the first in-depth exploration of the mental health treatment gap and its potential impact in Africa or any other LMIC setting. Although not observed nationally \[[@CR9]\], the study indicates a twofold reduction in the lifetime access gap since the first report of the treatment gap in the neighbouring district of Butajira 15 years earlier (90% vs. 42%) \[[@CR11], [@CR37]\]. This difference might have been partly due to the Butajira research project on severe mental disorders that has been operating over the past 15 years and supporting access to biomedical care \[[@CR12]\]. Therefore, people in our study site, which is only about 30 kms from Butajira, are more likely to benefit from the service in Butajira. However, key informants, particularly health extension workers, are more likely to recognise those with more severe illness and those who may already be known to the community and on treatment. This can underestimate the treatment gap. Nevertheless, even with the potentially underestimated treatment gap figure, the lifetime treatment gap remains too high and access to minimally adequate care unacceptably low. This study also demonstrates that equity may be an important issue as education and access behaviour were associated with access to biomedical care.

FTHs are the predominant source of care in the study area and more broadly in Ethiopia and will remain important in the longer term. Holy water treatment had good perceived benefit and satisfaction. However, there is no objective evidence that FTHs help in improving severe mental disorders \[[@CR38]\] and the self-reported improvement in this study might in part be to do with the religious consonance of the treatment modality, given most patients were Orthodox Christians. Objective investigation of potential benefits and potential synergy with biomedical care is required. Anecdotal experience suggests some of the FTH providers, such as *tenquay* (soothsayer)*,* are less acceptable and their use is likely to be higher than reported. Yet, given the higher rates of reported harms among users of these treatments, further investigation of their use and working with the public to ensure protection of patients is important.

Although families have some role in the care of patients with mental illness globally, the family is the "critical unit" \[[@CR39]\] of care in LMICs. Virtually all care in this setting is provided by the family. Despite the availability of a wide range of community resources, including nearly 300 social organisations, over 400 religious groups, NGOs and other resources in the study district \[[@CR40]\], access to such community resources was disappointingly low leaving the burden of care almost entirely on the family. Mobilising these resources through additional interventions, for example applying the Basic Needs model \[[@CR41]\] or the Community Based Rehabilitation Model that is being employed in an ongoing clinical trial study in the area \[[@CR42], [@CR43]\], may be important.

The high level of traumatic experiences such as physical restraint, homelessness and actual physical abuse of people with psychosis is of major concern. Although the traumatic experiences may not entirely be a direct result of the treatment gap, the large treatment gap is likely to be contributory to these negative experiences. In rural villages, people with psychosis induce fear and are perceived as unpredictable and violent \[[@CR44]\]. Such a perception, combined with lack of effective treatment, may lead to restraint and even other physical abuse. Preliminary work in the setting indicates that the lack of care alternatives may be the overriding reason for the physical restraint \[[@CR15]\]. The lack of legal mechanisms, low awareness among the public about mental disorders and the place of people with mental illness in society exposes people with mental illness to harm.

Scaling up mental healthcare is a crucial step for addressing the broader violation of the rights of people with mental illness \[[@CR45]\]. As shown, providing minimally adequate care may reduce these violations and victimisations although the study design would not allow us to confirm this conclusively.

Several limitations to this study are worth mentioning. First, the study is cross-sectional, yet many of the questions ask for lifetime recall. This was unavoidable because part of the focus of the study was intentionally lifetime experience as important index of the level of neglect. Second, although the tool for measuring treatment gap was developed carefully by mental health researchers and practitioners, including social workers, with understanding of the local context, the measure would benefit from further adaptation and simplifying. For example, the measure of the quality of care was assessed through satisfaction in care. Satisfaction is only one dimension of quality of care and evidently inadequate to evaluate quality of care; nevertheless, satisfaction may serve as a simple proxy measure in large population-based studies. Adequacy of care was also measured in a relatively crude way although the measure has been applied previously. We also conducted an analysis of association between adequacy of care for treatment received for the most recent episode and lifetime untoward experiences or abuses. This was carried out as an exploratory examination of the potential impact of the treatment gap. On the other hand, we expected that the pattern of neglect or abuse would be consistent over the course of the illness. If a patient is restrained in one episode, we anticipated that that patient is more likely to be restrained in subsequent episodes unless adequate treatment was provided. The effectiveness and recovery gaps were also not measured because doing so would require prospectively following up participants.

Conclusion {#Sec20}
==========

Viewing the treatment gap in psychosis as a multi-dimensional construct offers a more realistic and holistic understanding of the need for care and may assist policy and advocacy efforts. The community and NGOs can play a bigger role in supporting mental healthcare in rural Ethiopia. Our findings indicate the need to further increase service availability and the need to ensure adequacy of treatment. The use of other FTH is probably higher than reported; this study calls for further robust data on the benefits and harms of FTH and potential synergy with biomedical care. Cultural competence in protecting the dignity of people with mental illness should be a priority for providers and governments.

Supplementary information
=========================

 {#Sec21}

**Additional file 1.** Exploratory analysis of "adequacy" of treatment measured through frequency of visit to biomedical provider and relationship with measures of adverse illness outcomes.
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